For Healthcare Professionals

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma


About the study

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Histologically confirmed HB, HCN-NOS, or HCC with serum AFP >200ng/ml at the time of screening and following the most recent line of therapy.
  2. Disease reoccurrence after remission following initial standard-of-care (SOC) treatment (i.e. relapse) or failure of response to SOC treatment (i.e. refractory).
  3. Age ≥ 1 year and ≤ 21 years.
  4. Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject carries at least one HLA-A2 allele.
  5. Life expectancy of > 4 months per Principal Investigator's opinion.
  6. Lansky or Karnofsky Performance Scale ≥ 70.
  7. For enrollment to the dose-finding cohort, subjects must have at least one (1) lesion ≥ 5 mm in diameter or two (2) or more lesions ≥ 3 mm in diameter. For the dose-expansion cohort, subjects must have measurable disease by RECIST v1.1.
  8. Child-Pugh score of B7 or better.
  9. Adequate organ function.


Exclusion Criteria:

  1. Received the following within two (2) weeks of leukapheresis and within two (2) weeks of conditioning chemotherapy: cytotoxic chemotherapy, radiation, systemic corticosteroids, other anti-cancer therapies (including immunotherapeutic agents), or any other immunosuppressive agents (Note: use of inhaled or topical steroids is not exclusionary).
  2. Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study.
  3. Contraindication for receipt of conditioning chemotherapeutic agents including Fludarabine and Cyclophosphamide.
  4. Active autoimmune disease requiring systemic immunosuppressive therapy.
  5. Compromised circulation in the main portal vein, hepatic vein, or vena cava due to partial or complete obstruction which, in the opinion of the Principal Investigator, would make the subject unsuitable for the study.
  6. History of organ transplant.
  7. HB, HCN-NOS, or HCC involving greater than 50% of the liver (volumetric).
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 510-722-8719Email iconEmail Study Center

Study’s details


Hepatoblastoma,Hepatocellular Carcinoma (HCC),Liver Neoplasms,Metastatic Liver Cancer,Liver Cancer,HEMNOS

Age (in years)

1 - 21


Phase 1/Phase 2

Participants needed


Est. Completion Date

Jan 31, 2028

Treatment type



Eureka Therapeutics Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.